Since among leukemia/lymphomas CLL uniquely expresses high levels of FcμR on their surface, two types of immunotherapy targeting for the receptor have thus been developed for CLL cells. This evidence concerns the gene FCMR and B-cell chronic lymphocytic leukemia.